Completion Of Pembrolizumab In advanced non-small cell Lung cancer – real world Outcomes after Two years of therapy (COPILOT)
Immune checkpoint inhibitor (ICI)’s targeting the programmed-death-1/programmed-death ligand 1 (PD-1/PD-L1) axis have established themselves as part of the first line management of metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations. Pembrolizumab, an ICI directed against PD-1, has been shown in four practice changing first line phase III randomised controlled trials to improve overall survival alone, or in combination with chemotherapy, compared to chemotherapy alone in patients with advanced NSCLC1-4.